AbCellera Biologics (NASDAQ:ABCL) Given Overweight Rating at Piper Sandler

Piper Sandler restated their overweight rating on shares of AbCellera Biologics (NASDAQ:ABCL – Free Report) in a report published on Friday morning, Benzinga reports. They currently have a $20.00 price target on the stock. A number of other equities research analysts also recently commented on the company. The Goldman Sachs Group lowered their price objective […]

Related Keywords

Canada ,Piper Sandler ,Eli Lilly ,Abcellera Biologics ,Abcellera Biologics Company Profile ,Goldman Sachs Group ,National Bank ,Abcellera Biologics Inc ,Worth Asset Management ,Free Report ,Cellera Biologics ,Get Free Report ,Asset Management ,Capital Management ,Cellera Biologics Inc ,Confo Therapeutics ,Abcellera Biologics Daily ,Nasdaq Abcl ,Abcl ,Medical ,Reiterated Rating ,